Generated by AI
Kiora Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for retinal and other ophthalmic diseases. The company uses innovative small molecules to target pathways involved in vision loss, with programs designed to preserve, slow, or restore visual function. Its pipeline includes therapies under development for inherited retinal disorders, inflammatory eye conditions, and corneal repair applications, reflecting a specialization in diseases with limited treatment options. Kiora Pharmaceuticals Inc. works at the intersection of eye health and drug development, addressing both rare and more broadly relevant ophthalmic indications through its research and clinical programs. Headquartered in Encinitas, California, the company plays a niche role in the healthcare sector by advancing experimental therapies aimed at unmet needs in vision care.
Website332 Encinitas Boulevard
Encinitas, CA, 92024
United States
The latest articles about KPRX.
Detailed price information for Kiora Pharmaceuticals Inc. (KPRX-Q) from The Globe and Mail including charting and trades.
Summary of Apr 8's posts. Generated by AI.
Summary of Apr 7's posts. Generated by AI.
Clinical development executive brings over 20 years of ophthalmology experience supporting U.S. and global clinical trials to support the advancement of Kiora's pipeline and new asset opportunitiesEncinitas, California--(Newsfile Corp. - September 8, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced the appointment of Keith J. Lane, MBA, as Executive Vice President of Clinical Development and Regulatory Affairs. Mr. Lane has over 20 years of experience
Summary of Apr 7's posts. Generated by AI.
Investors talking about KPRX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.